Cosmo Entered into a License Agreement with Hyundai Pharm for Winlevi in Korea
Shots:
- Cassiopea will receive an up front & is also eligible to receive regulatory and sales milestones along with royalties on net sales
- Hyundai Pharm to get an exclusive right to register and commercialize Winlevi in the Republic of Korea while Cosmo will be the exclusive supplier of the product. Hyundai Pharm focuses to offer a new treatment option for both male and female acne patients in South Korea
- Winlevi was approved in the US as a novel drug with a unique mechanism of action for the topical treatment of acne in patients aged ≥12yrs. Acc. to IQVIA data, Winlevi was launched by Sun Pharma in the US in Nov 2021 and is already the most prescribed branded topical acne drug in the US
Ref: Cosmo Pharmaceuticals | Image: Cosmo Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
